Nevena Rebić1, Jamie Y Park2, Ria Garg2, Ursula Ellis3, Ayano Kelly4, Eileen Davidson5, Mary A De Vera1. 1. University of British Columbia and Collaboration for Outcomes Research and Evaluation, Vancouver, and Arthritis Research Canada, Richmond, British Columbia, Canada. 2. University of British Columbia and Collaboration for Outcomes Research and Evaluation, Vancouver, British Columbia, Canada. 3. University of British Columbia, Vancouver, British Columbia, Canada. 4. Australian National University and Canberra Rheumatology, Canberra, ACT, and The Children's Hospital at Westmead, Sydney, New South Wales, Australia. 5. Arthritis Research Canada, Richmond, British Columbia, Canada.
Abstract
OBJECTIVE: We aimed to identify, appraise, synthesize, and contextualize rapidly emerging reports on medication taking (adherence) among patients with rheumatic diseases during the COVID-19 pandemic. METHODS: We searched MEDLINE, EMBASE, and CINAHL for peer-reviewed communications, letters, and articles published during the COVID-19 pandemic evaluating medication taking among individuals with rheumatic diseases. We appraised assessment and reporting of medication adherence according to established definitions of 3 distinct problems of medication taking (i.e., noninitiation, poor implementation, and discontinuation) and pooled findings using random-effects models. RESULTS: We included 31 peer-reviewed studies in our synthesis from various jurisdictions, of which 25 described medication taking among rheumatology patients and 6 described medication prescribing among rheumatology providers. The pooled prevalence of overall medication nonadherence was 14.8% (95% confidence interval [95% CI] 12.3-17.2) and that of medication discontinuation (i.e., stopping of prescriptions) and poor implementation (i.e., not taking medication at the dose/frequency prescribed) as 9.5% (95% CI 5.1-14.0) and 9.6% (95% CI 6.2-13.0), respectively. Noninitiation (i.e., not starting/not filling new prescriptions) was not addressed. CONCLUSION: Medication taking among individuals with rheumatic diseases during the COVID-19 pandemic varies globally. Unclear reporting and extensive variation in research methods between studies create barriers to research replication, comparison, and generalization to specific patient populations. Future research in this area should use consistent and transparent approaches to defining and measuring medication taking problems to ensure that findings appropriately describe the epidemiology of medication adherence and have the potential to identify modifiable targets for improving patient care.
OBJECTIVE: We aimed to identify, appraise, synthesize, and contextualize rapidly emerging reports on medication taking (adherence) among patients with rheumatic diseases during the COVID-19 pandemic. METHODS: We searched MEDLINE, EMBASE, and CINAHL for peer-reviewed communications, letters, and articles published during the COVID-19 pandemic evaluating medication taking among individuals with rheumatic diseases. We appraised assessment and reporting of medication adherence according to established definitions of 3 distinct problems of medication taking (i.e., noninitiation, poor implementation, and discontinuation) and pooled findings using random-effects models. RESULTS: We included 31 peer-reviewed studies in our synthesis from various jurisdictions, of which 25 described medication taking among rheumatology patients and 6 described medication prescribing among rheumatology providers. The pooled prevalence of overall medication nonadherence was 14.8% (95% confidence interval [95% CI] 12.3-17.2) and that of medication discontinuation (i.e., stopping of prescriptions) and poor implementation (i.e., not taking medication at the dose/frequency prescribed) as 9.5% (95% CI 5.1-14.0) and 9.6% (95% CI 6.2-13.0), respectively. Noninitiation (i.e., not starting/not filling new prescriptions) was not addressed. CONCLUSION: Medication taking among individuals with rheumatic diseases during the COVID-19 pandemic varies globally. Unclear reporting and extensive variation in research methods between studies create barriers to research replication, comparison, and generalization to specific patient populations. Future research in this area should use consistent and transparent approaches to defining and measuring medication taking problems to ensure that findings appropriately describe the epidemiology of medication adherence and have the potential to identify modifiable targets for improving patient care.
Authors: James Todd Rosenbaum; Hedley Hamilton; Dongseok Choi; Michael H Weisman; John D Reveille; Kevin L Winthrop Journal: Ann Rheum Dis Date: 2020-06-10 Impact factor: 19.103
Authors: Lena Mostafa Hassen; Ibrahim A Almaghlouth; Ikhlass Mostafa Hassen; Maha H Daghestani; Amal A Almohisen; Eman M Alqurtas; Abdulaziz Alkhalaf; Mohammed K Bedaiwi; Mohammed A Omair; Sultan M Almogairen; Hussein F Alarfaj; Abdulrahman S Alarfaj Journal: Int J Rheum Dis Date: 2020-09-17 Impact factor: 2.454
Authors: Bella Mehta; Deanna Jannat-Khah; Carol A Mancuso; Anne R Bass; Carine J Moezinia; Allan Gibofsky; Susan M Goodman; Said Ibrahim Journal: Semin Arthritis Rheum Date: 2020-07-06 Impact factor: 5.532
Authors: Richard O Akintayo; Akpabio A Akpabio; Asgar A Kalla; Dzifa Dey; Angela N Migowa; Hakeem Olaosebikan; Rachid Bahiri; Yasser El Miedany; Djohra Hadef; Wafa Hamdi; Omondi Oyoo; Samy Slimani; Abubakar Yerima; Yassmin Taha; Adewale O Adebajo; Olufemi O Adelowo; Mohammed Tikly; Imad Ghozlani; Kawther Ben Abdelghani; Nermeen A Fouad; Doaa Mosad; Dalia El Mikkawy; Mohamed Hassan Abu-Zaid; Rasha A Abdel-Magied Journal: Rheumatology (Oxford) Date: 2021-01-05 Impact factor: 7.580